Redefining Success
She started Bharat Biotech with her husband in 1996. Today, 20 years later, her company holds a portfolio of 50 patents and has delivered over 3 billion doses of vaccines to 65 countries across the globe. Jasleen Kaur | March 2016 Issue | The Dollar Business Suchitra K. Ella, Co-Founder & JMD, Bharat Biotech Intl. Ltd. When she decided to take the entrepreneurial plunge she was equipped with all the right tools – enthusiasm, self-confidence, training, and most importantly, her husband’s passion for developing new IPRs (intellectual property) and technology platforms in vaccine development. She was determined to build a socially-inclined enterprise and Bharat Biotech, India’s well-known multi-dimensional biotechnology company is doing precisely that. For her, it was a path quite different from ...
Data integrity critical for growth of pharma and bio-tech sectors
Jayarama Emani | The Dollar Business Two days after the Prime Minister of India, Narendra Modi launched India’s first indigenously developed and manufactured Rotavirus vaccine-‘Rotavac’ in which, Bharat Biotech played a crucial role in developing and testing the vaccine along with the Gates Foundation, its co-founder, Dr Krishna Ella, says that data integrity and trust are two key areas that will be affecting India’s progress in the pharmaceutical and bio-technology sectors. Speaking exclusively to The Dollar Business on the side-lines of the first Confederation of Indian Industry (CII) meeting and public session on “Mapping Industrial Growth By Tapping Sectors of Advantage in Telangana,” Dr Ella says that loss of credibility not only affects the company, but the nation as a ...
Indias first indigenous vaccine launched; initiative likely to boost R&D
The Dollar Business Bureau The Prime Minister of India, Narendra Modi, on Monday, launched India’s first indigenously developed and manufactured Rotavirus vaccine-‘Rotavac’ and also appreciated the partners involved in the development of the advanced indigenous vaccine. The Prime Minister mentioned this initiative as a successful example of collaboration between India and the United States in the area of medical research. He also noted the initiative as an example for India’s capabilities in high-end Research& Development (R&D), manufacturing of highly sophisticated pharma products and effective finding of affordable solutions to societal problems under Public-Private Partnership (PPP) model. Narendra Modi further hoped that this initiative would provide a basis for furthering R&D and manufacturing activities in India not only in medical ...
